Rallybio Corporation (NASDAQ:RLYB) Short Interest Update

Rallybio Corporation (NASDAQ:RLYB) was the recipient of a significant decrease in short interest during the month of February. As of February 13th, there was short interest totaling 38,974 shares, a decrease of 72.5% from the January 29th total of 141,643 shares. Based on an average daily volume of 24,991 shares, the short-interest ratio is currently 1.6 days. Currently, 0.8% of the shares of the stock are short sold. Currently, 0.8% of the shares of the stock are short sold. Based on an average daily volume of 24,991 shares, the short-interest ratio is currently 1.6 days.

Rallybio Price Performance

Shares of Rallybio stock opened at $7.54 on Friday. The company’s 50 day moving average price is $5.36 and its two-hundred day moving average price is $5.06. The firm has a market capitalization of $39.81 million, a P/E ratio of -2.95 and a beta of -1.05. Rallybio has a fifty-two week low of $1.76 and a fifty-two week high of $7.78.

Analyst Ratings Changes

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Rallybio in a report on Monday, December 29th. Four equities research analysts have rated the stock with a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Reduce” and a consensus target price of $40.00.

Hedge Funds Weigh In On Rallybio

A number of institutional investors and hedge funds have recently bought and sold shares of RLYB. XTX Topco Ltd raised its position in Rallybio by 64.6% in the fourth quarter. XTX Topco Ltd now owns 97,313 shares of the company’s stock valued at $67,000 after purchasing an additional 38,205 shares during the last quarter. Susquehanna International Group LLP increased its stake in shares of Rallybio by 485.9% in the third quarter. Susquehanna International Group LLP now owns 136,294 shares of the company’s stock valued at $68,000 after buying an additional 113,031 shares during the period. Geode Capital Management LLC raised its holdings in Rallybio by 1.2% in the 4th quarter. Geode Capital Management LLC now owns 248,005 shares of the company’s stock valued at $170,000 after buying an additional 2,996 shares during the last quarter. Citadel Advisors LLC boosted its position in Rallybio by 576.1% during the 3rd quarter. Citadel Advisors LLC now owns 438,705 shares of the company’s stock worth $219,000 after buying an additional 373,821 shares during the period. Finally, Renaissance Technologies LLC grew its holdings in Rallybio by 16.9% during the 4th quarter. Renaissance Technologies LLC now owns 835,692 shares of the company’s stock worth $573,000 after acquiring an additional 120,892 shares during the last quarter. Institutional investors and hedge funds own 90.34% of the company’s stock.

About Rallybio

Rallybio Therapeutics, Inc (NASDAQ: RLYB) is a clinical‐stage biotechnology company focused on developing and commercializing therapies for people living with rare genetic diseases. The company’s scientific approach leverages diverse modalities—including monoclonal antibodies, small molecules and enzyme replacement—to address high‐unmet‐need conditions in areas such as immunodeficiency, metabolic disorders and dermatologic diseases. Rallybio’s pipeline is designed to advance through registrational clinical trials with the goal of delivering first‐in‐class or best‐in‐class therapies to patients who currently have limited or no approved treatment options.

Among Rallybio’s lead programs is RBX‐100, an investigational therapy for congenital athymia, a rare pediatric immunodeficiency.